GSTM1 , GSTT1 , and GSTP1 polymorphisms and colorectal cancer risk in Polish nonsmokers

Glutathione S-transferase (GST) enzymes are responsible for cellular detoxification of many carcinogens and are important anticancer elements. This study assessed potential relationships between , , and polymorphisms and colorectal cancer (CRC) risk in Polish nonsmokers. We also analyzed the influen...

Full description

Saved in:
Bibliographic Details
Published inOncotarget Vol. 9; no. 30; pp. 21224 - 21230
Main Authors Klusek, Justyna, Nasierowska-Guttmejer, Anna, Kowalik, Artur, Wawrzycka, Iwona, Lewitowicz, Piotr, Chrapek, Magdalena, Głuszek, Stanisław
Format Journal Article
LanguageEnglish
Published United States Impact Journals LLC 20.04.2018
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Glutathione S-transferase (GST) enzymes are responsible for cellular detoxification of many carcinogens and are important anticancer elements. This study assessed potential relationships between , , and polymorphisms and colorectal cancer (CRC) risk in Polish nonsmokers. We also analyzed the influence of gene polymorphisms on CRC clinical and histopathological features. Our study included 197 CRC patients and 104 healthy controls. , , and polymorphisms were evaluated using qPCR. Polymorphism frequencies observed in our control group corresponded to those in other European populations. The and genotypes were observed with similar frequencies in both CRC patients and controls ( : 46.7% vs. 45.2%; : 15.7% vs. 20.2%). , , and genotype frequencies were respectively 42.1%, 48.2%, and 9.6% in patients and 48.1%, 42.3%, and 9.6% in controls. polymorphism correlated with higher tumor grade in CRC patients, and the genotype was associated with more frequent metastasis to lymph nodes (pN classification). Our results suggest that gene polymorphisms may influence CRC tumor grade and stage.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.25031